Vonetize Plc: Update regarding the sale of the controlling shareholders’ shares to US based Desilu Studios Inc.; target price unchanged at NIS 1.43 jaimeuss_admin 17 בSeptember 2018 Research 0 Comments Continue Reading
Brainsway Ltd: The company’s main competitor has completed an IPO, providing for a new benchmark to Brainsway’s valuation; target price unchanged. jaimeuss_admin 17 בSeptember 2018 Research 0 Comments Continue Reading
RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59 jaimeuss_admin 16 בSeptember 2018 Research 0 Comments Continue Reading
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc) Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2. jaimeuss_admin 6 בSeptember 2018 Research 0 Comments Continue Reading
Enlight Renewable Energy Ltd: Significant regualtory progress brings Enlight closer to final-stage approvals for the Bereshit wind farm; stock target price unchanged. jaimeuss_admin 6 בSeptember 2018 Research 0 Comments Continue Reading
Entera Bio Ltd., a subsidiary of DNA Biomedical Solutions Ltd. has announced the share pricing for its forthcoming IPO (Nasdaq); As pricing was at similar valuation to our initiation report, target price remains unchanged. jaimeuss_admin 30 בAugust 2018 Research 0 Comments Continue Reading